NCT04229030View on ClinicalTrials.gov

RZL-012 for Dercum's Disease Lipomas

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

February 20, 2021

Study Completion Date

February 20, 2021

Conditions
Dercum's Disease Lipomas
Interventions
DRUG

RZL-012

small synthetic molecule for the treatment of Dercum's Disease lipomas

DRUG

Vehicle

Vehicle of RZL-012 drug product

Trial Locations (1)

90025

Limitless Therapeutics, Los Angeles

All Listed Sponsors
lead

Raziel Therapeutics Ltd.

INDUSTRY

NCT04229030 - RZL-012 for Dercum's Disease Lipomas | Biotech Hunter | Biotech Hunter